ClinConnect ClinConnect Logo
Search / Trial NCT07076121

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Launched by BRISTOL-MYERS SQUIBB · Jul 14, 2025

Trial Information

Current as of July 26, 2025

Not yet recruiting

Keywords

Prmt5 Mtap Mrtx1719 Mountain Tap Pancreatic Cancer Pdac

ClinConnect Summary

This clinical trial is studying a new treatment option for people with a type of advanced pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC). Specifically, it’s looking at whether adding a medicine called BMS-986504 to a standard chemotherapy treatment (nab-paclitaxel and gemcitabine) is safe and helps control the cancer better than chemotherapy alone. This study focuses on patients whose tumors have a specific genetic change known as homozygous MTAP deletion, which may make them respond differently to this new treatment.

To join this study, participants need to have confirmed metastatic pancreatic cancer that has not been treated with systemic therapy before, and their tumor must show the MTAP deletion. Patients should have at least one measurable tumor and must be adults between 65 and 74 years old. Participants may have received one initial cycle of the standard chemotherapy but no more before starting the study. During the trial, patients will receive either the new medication plus chemotherapy or a placebo (a treatment with no active medicine) plus chemotherapy. The goal is to see how well the new medicine works and how safe it is. It’s important to know that this trial is not yet open for enrollment, and certain other health conditions or recent cancers may prevent someone from joining.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC).
  • Evidence of homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss detected in tumor tissue.
  • Metastatic disease with at least 1 measurable lesion as per Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1).
  • Participants must not have received any systemic anticancer treatments in the metastatic setting.
  • If clinically indicated and as per investigator discretion, participants may receive up to 1 cycle of Nab-paclitaxel/Gemcitabine (nab-p/gem) in the metastatic setting and must have not progressed or required discontinuation due to intolerable toxicity.
  • Initial cycle of nab-p/gem administered in the metastatic setting must have been completed prior to randomization.
  • Exclusion Criteria:
  • Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.

About Bristol Myers Squibb

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.

Locations

Taipei, , Taiwan

Hradec Kralove, , Czechia

Madrid, , Spain

Sevilla, , Spain

Milwaukee, Wisconsin, United States

New York, New York, United States

Santiago, , Chile

Santiago, , Chile

Solna, , Sweden

Phoenix, Arizona, United States

Springdale, Arkansas, United States

San Francisco, California, United States

Jacksonville, Florida, United States

Tampa, Florida, United States

Marietta, Georgia, United States

Boise, Idaho, United States

Chicago, Illinois, United States

Westwood, Kansas, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Detroit, Michigan, United States

Grand Rapids, Michigan, United States

Rochester, Minnesota, United States

Omaha, Nebraska, United States

Buffalo, New York, United States

New Hyde Park, New York, United States

New York, New York, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Portland, Oregon, United States

Portland, Oregon, United States

Bethlehem, Pennsylvania, United States

Lancaster, Pennsylvania, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Nashville, Tennessee, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Houston, Texas, United States

Fairfax, Virginia, United States

Seattle, Washington, United States

Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

Abb, , Argentina

San Miguel De Tucuman, , Argentina

Buenos Aires, , Argentina

Córdoba, , Argentina

St Leonards, New South Wales, Australia

Brisbane, Queensland, Australia

Brisbane, Queensland, Australia

Woodville, South Australia, Australia

Malvern, Victoria, Australia

Melbourne, Victoria, Australia

Murdoch, Western Australia, Australia

Linz, , Austria

Salzburg, , Austria

Wien, , Austria

Bonheiden, Antwerpen, Belgium

Edegem, Antwerpen, Belgium

Brussels, , Belgium

Brussels, , Belgium

Gent, Oost Vlaanderen, Belgium

Leuven, Vlaams Brabant, Belgium

Liège, , Belgium

Salvador, Bahia, Brazil

Vitória, , Brazil

Belo Horizonte, Minas Gerais, Brazil

Natal, Rio Grande Do Norte, Brazil

Santa Cruz Do Sul, Rio Grande Do Sul, Brazil

Barretos, , Brazil

Rio De Janeiro, , Brazil

São Paulo, , Brazil

São Paulo, , Brazil

Calgary, Alberta, Canada

Vancouver, British Columbia, Canada

Halifax, Nova Scotia, Canada

Toronto, Ontario, Canada

Toronto, Ontario, Canada

Montreal, Quebec, Canada

Santiago, , Chile

Viña Del Mar, , Chile

Hefei, Anhui, China

Hefei, Anhui, China

Beijing, Beijing, China

Beijing, Beijing, China

Chongqing, Chongqing, China

Fuzhou, Fujian, China

Fuzhou, Fujian, China

Guangzhou, Guangdong, China

Harbin, Heilongjiang, China

Luoyang, Henan, China

Wuhan, Hubei, China

Changsha, Hunan, China

Nanjing, Jiangsu, China

Nanjing, Jiangsu, China

Shenyang, Liaoning, China

Xi'an, Shaanxi, China

Jinan, Shandong, China

Jining, Shandong, China

Shanghai Shi, Shanghai, China

Shanghai, Shanghai, China

Shanghai, Shanghai, China

Cheng Du, Sichuan, China

Chengdu, Sichuan, China

Tianjin, Tianjin, China

Hangzhou, Zhejiang, China

Medellín, Antioquia, Colombia

Montería, , Colombia

Pereira, Risaralda, Colombia

Bogotá, , Colombia

Brno, , Czechia

Olomouc, , Czechia

Prague, , Czechia

Praha, , Czechia

Praha 2, , Czechia

Copenhagen, Hovedstaden, Denmark

Aarhus, Midtjylland, Denmark

Aalborg, Nordjylland, Denmark

Odense, Syddanmark, Denmark

Vejle, Syddanmark, Denmark

Clermont Ferrand, Auvergne, France

Dijon, , France

Besançon, Doubs, France

Toulouse, Haute Garonne, France

Saint Cloud, Hauts De Seine, France

Montpellier, , France

Vandoeuvre Lès Nancy, Meurthe Et Moselle, France

Marseille, , France

Bayonne, , France

Lyon, , France

Villejuif, Val De Marne, France

Poitiers, Vienne, France

Paris, , France

Villejuif, , France

München, Bayern, Germany

Frankfurt, Hessen, Germany

Göttingen, Niedersachsen, Germany

Bochum, Nordrhein Westfalen, Germany

Chemnitz, Sachsen, Germany

Dresden, Sachsen, Germany

Berlin, , Germany

Hamburg, , Germany

Köln, , Germany

Ulm, , Germany

Athens, , Greece

Athens, , Greece

Heraklion, , Greece

Thessaloniki, , Greece

Thessaloniki, , Greece

Larissa, , Greece

Athens, , Greece

Hong Kong, , Hong Kong

Shatin, , Hong Kong

New Delhi, Delhi, India

Kochi, Kerala, India

Bhubaneswar, Odisha, India

Hyderabad, Telangana, India

Hyderabad, Telangana, India

Varanasi, Uttar Pradesh, India

Kolkata, West Bengal, India

Dublin, , Ireland

Ramat Gan, Hamerkaz, Israel

Zerifin, Hamerkaz, Israel

Afula, Hatsafon, Israel

Tel Aviv, , Israel

Jerusalem, Yerushalayim, Israel

Petah Tikva, , Israel

Naples, Campania, Italy

Meldola, Emilia Romagna, Italy

Roma, Lazio, Italy

Milan, Lombardia, Italy

Rozzano, Milano, Italy

Pisa, Toscana, Italy

Padova, Veneto, Italy

Milano, , Italy

Verona, , Italy

Nagoya, Aichi, Japan

Kashiwa, Chiba, Japan

Sapporo, Hokkaido, Japan

Yokohama, Kanagawa, Japan

Chuo Ku, Tokyo, Japan

Koto, Tokyo, Japan

Osaka, , Japan

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Kuching, Sarawak, Malaysia

Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

Lembah Pantai, Wilayah Persekutuan Kuala Lumpur, Malaysia

Cuauhtémoc, Ciudad De México, Distrito Federal, Mexico

Mexico City, Distrito Federal, Mexico

Monterrey, , Mexico

Oaxaca De Juarez, Oaxaca, Mexico

Mexico City, , Mexico

Puebla, , Mexico

Maastricht, Limburg, Netherlands

Breda, Noord Brabant, Netherlands

Leiden, Zuid Holland, Netherlands

Rotterdam, Zuid Holland, Netherlands

Warszawa, Mazowieckie, Poland

Gdask, Pomorskie, Poland

Poznań, Wielkopolskie, Poland

Cluj Napoca, Cluj, Romania

Florești, Cluj, Romania

Craiova, Dolj, Romania

Ploiești, Prahova, Romania

București, , Romania

București, , Romania

Cluj, , Romania

Cluj, , Romania

Iași, , Romania

Singapore, Central Singapore, Singapore

Singapore, , Singapore

Singapore, , Singapore

Singapore, , Singapore

Banska Bystrica, , Slovakia

Kosice, , Slovakia

Trencin, , Slovakia

Bratislava, , Slovakia

Johannesburg, Gauteng, South Africa

Pretoria, Gauteng, South Africa

Soweto, Gauteng, South Africa

Cape Town, Western Cape, South Africa

Barcelona, , Spain

Barcelona, , Spain

Madrid, , Spain

Madrid, , Spain

Zaragoza, , Spain

Lund, , Sweden

Uppsala, , Sweden

Gothenburg, , Sweden

Bern, Berne, Switzerland

St.Gallen, Sankt Gallen, Switzerland

Bellinzona, Ticino, Switzerland

Geneva, , Switzerland

Taichung, , Taiwan

Taipei, , Taiwan

Taoyuan, , Taiwan

Stanbul, , Turkey

Adana, , Turkey

Ankara, , Turkey

Ankara, , Turkey

Istanbul, , Turkey

Birmingham, England, United Kingdom

London, England, United Kingdom

London, Kensington And Chelsea, United Kingdom

London, , United Kingdom

London, , United Kingdom

Wirral, , United Kingdom

Guangzhou, Guangdong, China

Zhengzhou, Henan, China

Wuhan, Hubei, China

Changzhou, Jiangsu, China

Shanghai, Shanghai, China

Taiyuan, Shanxi, China

Hangzhou, Zhejiang, China

Patients applied

0 patients applied

Trial Officials

Bristol-Myers Squibb

Study Director

Bristol-Myers Squibb

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported